Drug Profile
Research programme: navacims - Parvus Therapeutics
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator University of Calgary
- Developer Parvus Therapeutics
- Class Anti-inflammatories; Antihypercalcaemics; Antirheumatics; Eye disorder therapies; Hepatoprotectants
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Coeliac disease; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis
Most Recent Events
- 31 Aug 2023 Preclinical development is ongoing in Inflammatory-bowel-diseases in Canada (Parvus Therapeutics pipeline; August 2023)
- 31 Aug 2023 Preclinical development is ongoing in Type-1 diabetes mellitus in Canada (Parvus Therapeutics pipeline; August 2023)
- 31 Aug 2023 Preclinical development is ongoing in Coeliac disease in Canada (Parvus Therapeutics pipeline; August 2023)